Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Accumulated Expenses (2019 - 2025)

Korro Bio (KRRO) has disclosed Accumulated Expenses for 6 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 8.03% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Sep 2025, up 8.03%, and an annual FY2024 reading of $3.8 million, down 63.03% over the prior year.
  • Accumulated Expenses was $3.3 million for Q3 2025 at Korro Bio, up from $2.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.2 million in Q4 2023 and bottomed at $1.9 million in Q3 2023.
  • Average Accumulated Expenses over 5 years is $4.0 million, with a median of $3.5 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 289.18% in 2023, then tumbled 63.03% in 2024.
  • Year by year, Accumulated Expenses stood at $4.4 million in 2021, then tumbled by 40.02% to $2.6 million in 2022, then surged by 289.18% to $10.2 million in 2023, then crashed by 63.03% to $3.8 million in 2024, then fell by 12.34% to $3.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for KRRO at $3.3 million in Q3 2025, $2.3 million in Q2 2025, and $3.6 million in Q1 2025.